We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Merck and Co Inc | NYSE:MRK | NYSE | Common Stock |
| Price Change | % Change | Share Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|
| -0.63 | -0.49% | 128.66 | 129.25 | 128.0269 | 129.25 | 6,064,068 | 21:15:03 |
From May 2021 to May 2024
By Colin Kellaher
Evaxion Biotech A/S on Monday said it plans a Phase 2b study of EVX-01, its lead product candidate, in combination with Merck & Co.'s blockbuster cancer drug Keytruda in patients with the skin cancer melanoma.
The Copenhagen biotechnology company said it will be responsible for conducting the study, which it expects to launch by the end of the year, while Merck will supply all of the necessary Keytruda and will continue to collaborate as the study data mature.
Evaxion said the planned multicenter trial will enroll patients with metastatic stage III and stage IV melanoma.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
October 25, 2021 06:13 ET (10:13 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
1 Year Merck Chart |
1 Month Merck Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
